Mortality of non-participants in cervical screening: Register-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Mortality of non-participants in cervical screening : Register-based cohort study. / Dugué, Pierre-Antoine; Lynge, Elsebeth; Rebolj, Matejka.

In: International Journal of Cancer, Vol. 134, No. 11, 01.06.2014, p. 2674–2682.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Dugué, P-A, Lynge, E & Rebolj, M 2014, 'Mortality of non-participants in cervical screening: Register-based cohort study', International Journal of Cancer, vol. 134, no. 11, pp. 2674–2682. https://doi.org/10.1002/ijc.28586

APA

Dugué, P-A., Lynge, E., & Rebolj, M. (2014). Mortality of non-participants in cervical screening: Register-based cohort study. International Journal of Cancer, 134(11), 2674–2682. https://doi.org/10.1002/ijc.28586

Vancouver

Dugué P-A, Lynge E, Rebolj M. Mortality of non-participants in cervical screening: Register-based cohort study. International Journal of Cancer. 2014 Jun 1;134(11):2674–2682. https://doi.org/10.1002/ijc.28586

Author

Dugué, Pierre-Antoine ; Lynge, Elsebeth ; Rebolj, Matejka. / Mortality of non-participants in cervical screening : Register-based cohort study. In: International Journal of Cancer. 2014 ; Vol. 134, No. 11. pp. 2674–2682.

Bibtex

@article{f235902f466349eeb97b80381a210dca,
title = "Mortality of non-participants in cervical screening: Register-based cohort study",
abstract = "The selective uptake of screening by healthy participants and its impact on the evaluation of screening effectiveness in non-randomized studies have been discussed, but hardly studied. We quantified excess mortality among cervical screening non-participants compared to participants. Based on Danish healthcare registers, we determined women's participation in cervical screening in 1990-1993 (one screening round) and 1990-1997 (two screening rounds). Women were followed until end of 2010. We computed hazard ratios (HR) comparing non-participants' and participants' risk of death, and analyzed the impact of age, calendar period of screening evaluation, screening intensity, length of follow-up and cause of death. After one screening round, the 17-year HR of death in non-participants was 1.61 (95% CI: 1.59-1.63), with an increasing trend over calendar time. After two rounds, regular non-participants had a HR of 2.09 (95% CI: 2.05-2.14) compared to regular participants. The HR for human papillomavirus (HPV)-related cancers other than cervical cancer was 3.80 (95% CI: 2.67-5.41). Younger women, whose coverage rates were higher, had higher all-cause mortality HRs. Women screened more frequently than recommended had the same mortality as those screened as recommended. Acute illness did not seem to be a major reason for non-participation, as the excess risk of death was not higher in the first years following screening evaluation. Non-participants in cervical screening had substantially higher all-cause mortality than participants, and a particularly increased risk of HPV-related causes of death. These results indicate that improper control for the selective uptake of cervical screening may result in overestimating its effectiveness.",
author = "Pierre-Antoine Dugu{\'e} and Elsebeth Lynge and Matejka Rebolj",
note = "{\textcopyright} 2013 UICC.",
year = "2014",
month = jun,
day = "1",
doi = "10.1002/ijc.28586",
language = "English",
volume = "134",
pages = "2674–2682",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - Mortality of non-participants in cervical screening

T2 - Register-based cohort study

AU - Dugué, Pierre-Antoine

AU - Lynge, Elsebeth

AU - Rebolj, Matejka

N1 - © 2013 UICC.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - The selective uptake of screening by healthy participants and its impact on the evaluation of screening effectiveness in non-randomized studies have been discussed, but hardly studied. We quantified excess mortality among cervical screening non-participants compared to participants. Based on Danish healthcare registers, we determined women's participation in cervical screening in 1990-1993 (one screening round) and 1990-1997 (two screening rounds). Women were followed until end of 2010. We computed hazard ratios (HR) comparing non-participants' and participants' risk of death, and analyzed the impact of age, calendar period of screening evaluation, screening intensity, length of follow-up and cause of death. After one screening round, the 17-year HR of death in non-participants was 1.61 (95% CI: 1.59-1.63), with an increasing trend over calendar time. After two rounds, regular non-participants had a HR of 2.09 (95% CI: 2.05-2.14) compared to regular participants. The HR for human papillomavirus (HPV)-related cancers other than cervical cancer was 3.80 (95% CI: 2.67-5.41). Younger women, whose coverage rates were higher, had higher all-cause mortality HRs. Women screened more frequently than recommended had the same mortality as those screened as recommended. Acute illness did not seem to be a major reason for non-participation, as the excess risk of death was not higher in the first years following screening evaluation. Non-participants in cervical screening had substantially higher all-cause mortality than participants, and a particularly increased risk of HPV-related causes of death. These results indicate that improper control for the selective uptake of cervical screening may result in overestimating its effectiveness.

AB - The selective uptake of screening by healthy participants and its impact on the evaluation of screening effectiveness in non-randomized studies have been discussed, but hardly studied. We quantified excess mortality among cervical screening non-participants compared to participants. Based on Danish healthcare registers, we determined women's participation in cervical screening in 1990-1993 (one screening round) and 1990-1997 (two screening rounds). Women were followed until end of 2010. We computed hazard ratios (HR) comparing non-participants' and participants' risk of death, and analyzed the impact of age, calendar period of screening evaluation, screening intensity, length of follow-up and cause of death. After one screening round, the 17-year HR of death in non-participants was 1.61 (95% CI: 1.59-1.63), with an increasing trend over calendar time. After two rounds, regular non-participants had a HR of 2.09 (95% CI: 2.05-2.14) compared to regular participants. The HR for human papillomavirus (HPV)-related cancers other than cervical cancer was 3.80 (95% CI: 2.67-5.41). Younger women, whose coverage rates were higher, had higher all-cause mortality HRs. Women screened more frequently than recommended had the same mortality as those screened as recommended. Acute illness did not seem to be a major reason for non-participation, as the excess risk of death was not higher in the first years following screening evaluation. Non-participants in cervical screening had substantially higher all-cause mortality than participants, and a particularly increased risk of HPV-related causes of death. These results indicate that improper control for the selective uptake of cervical screening may result in overestimating its effectiveness.

U2 - 10.1002/ijc.28586

DO - 10.1002/ijc.28586

M3 - Journal article

C2 - 24288241

VL - 134

SP - 2674

EP - 2682

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -

ID: 97383625